Royalty Pharma
RPRX
RPRX
312 hedge funds and large institutions have $8.16B invested in Royalty Pharma in 2023 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 138 increasing their positions, 113 reducing their positions, and 46 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
12% less capital invested
Capital invested by funds: $9.31B → $8.16B (-$1.15B)
24% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 46
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Holders
312
Holding in Top 10
6
Calls
$40.5M
Puts
$11.8M
Top Buyers
| 1 | +$32.3M | |
| 2 | +$29.2M | |
| 3 | +$28.5M | |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$28.5M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
+$25.2M |
Top Sellers
| 1 | -$444M | |
| 2 | -$93.8M | |
| 3 | -$57.9M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$44.6M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
-$38.6M |